Biocon Ltd, a leading biopharmaceutical company, has announced its financial results for the fourth quarter of FY2024-25, showcasing a remarkable 153% year-on-year (YoY) increase in net profit to ₹344 crore. The company attributes this surge to strong operational performance across its generics, biologics, and research services divisions.
Financial Highlights
- Total revenue for Q4 FY25 stood at ₹4,454 crore, marking a 12% YoY growth.
- EBITDA rose 16% YoY to ₹1,115 crore, with an EBITDA margin of 25%.
- Profit before tax (PBT) increased 53% YoY to ₹487 crore.
- Generics business revenue surged 46% YoY to ₹1,048 crore, driven by new product launches.
- Biocon Biologics revenue grew 9% YoY to ₹2,463 crore, supported by market share gains.
- Syngene, Biocon’s research arm, recorded an 11% revenue growth to ₹1,018 crore.
Strategic Developments & Expansion Plans
Biocon continues to strengthen its global presence with the launch of Liraglutide in the UK, marking its entry into the GLP-1 therapy segment. The company also expanded its biologics manufacturing footprint through the acquisition of a state-of-the-art facility in the US.
Additionally, Biocon’s board has approved a plan to raise up to ₹4,500 crore through various modes, including qualified institutional placement (QIP) and rights issue, to support future growth initiatives.
Dividend Declaration & Market Performance
The board has recommended a final dividend of ₹0.50 per equity share (10% of face value), subject to shareholder approval. Following the earnings announcement, Biocon’s shares closed 3% lower at ₹334.60 on the BSE.
With a strong financial outlook and strategic expansion plans, Biocon remains committed to innovation and operational excellence in the biopharmaceutical sector.
